Combined fluticasone furoate/vilanterol reduces decline in lung function following inhaled allergen 23 h after dosing in adult asthma: a randomised, controlled trial

Table 2 Statistical analysis ^a of treatment differences in change from post-saline baseline (intent-to-treat population)

	Treatment difference	95% CI
wmFEV ₁ (L)
FF – placebo	0.162	0.087, 0.237
FF/VI – placebo	0.145	0.069, 0.222
FF/VI – FF	−0.017	−0.091, 0.057
Max. percent decrease (%)
FF – placebo	10.951	8.053, 13.848
FF/VI – placebo	11.785	8.849, 14.721
FF/VI – FF	0.834	−2.010, 3.678
Max. absolute decrease in FEV ₁ (L)
FF – placebo	0.330	0.232, 0.429
FF/VI – placebo	0.331	0.231, 0.431
FF/VI – FF	0.001	−0.096, 0.097

^aPopulation sizes analysed: placebo, n = 45; FF, n = 49; FF/VI, n = 46. Efficacy endpoints were analysed using a mixed-effects analysis of covariance (ANCOVA) model, with fixed effects of treatment, period, subject-level baseline, period-level baseline, country, sex and age and subject fitted as a random effect.
CI = confidence interval; FEV₁ = forced expiratory volume in 1 s; FF = fluticasone furoate; L = litres; VI = vilanterol; wm = weighted mean.

ISSN: 2045-7022